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SUMMARY: 
 
Background: 
Olfactory dysfunction is an increasingly recognised condition, associated with reduced 
quality of life and major health outcomes such as neurodegeneration and death. However, 
translational research in this field is limited by heterogeneity in methodological approach, 
including definitions of impairment, improvement and appropriate assessment techniques. 
Accordingly, effective treatments are limited. In an effort to encourage high quality and 
comparable work in this field, among others, we propose the following ideas and 
recommendations. Whilst full recommendations are outlined in the main document, key 
points include: 
 
 Patients with suspected olfactory loss should undergo a full examination of the head 
and neck, including rigid nasal endoscopy.  
 Subjective olfactory assessment should not be undertaken in isolation, given its poor 
reliability. 
 Psychophysical assessment tools used in clinical and research settings should include 
reliable and validated tests of odour threshold, and/or one of odour identification or 
discrimination.  
 Comprehensive chemosensory assessment should include gustatory screening. 
 Smell training can be helpful in patients with olfactory loss of several aetiologies. 
 
 
 
Conclusions: 
We hope the current manuscript will encourage clinicians and researchers to adopt a common 
language, and in so doing, increase the methodological quality, consistency and 
generalisability of work in this field.  
 
 
 Word Count: 198 
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Introduction 
 
Olfactory dysfunction is an increasingly recognised condition. However, the sense of smell 
remains relatively poorly researched and is often neglected by the medical community: in 
2007 a UK-based survey found that whilst 97% of consultant otorhinolaryngologists managed 
olfactory dysfunction, 55% did not formally test for chemosensory impairment, and of those 
who did, only 12% did so routinely (1). 
 
This putative neglect may be due to the perceived subtle effects of olfactory dysfunction and 
frustration at the apparent lack of treatment options. However, there is increasing evidence 
that olfactory impairment can affect quality of life, through environmental and social anxiety, 
food and weight disturbances and depression (2–7). Moreover, a growing body of evidence 
connects olfaction to major health outcomes, including neurodegenerative disease and death 
(8,9). It is therefore important that olfactory dysfunction is both investigated and treated where 
possible, particularly amongst ENT specialists. This is reflected in the recent inclusion of 
olfactory impairment as part of the ENT-UK ‘GENERATE’ national agenda for research (10), 
as well as continued emphasis within the United States National Institutes of Health/National 
Institute on Deafness and Other Communication Disorders strategic plan (11).  
 
At present, the literature on olfaction is limited by heterogeneity in methodological approach. 
This heterogeneity is reflected in varying definitions of impairment and improvement, lack of 
consensus regarding appropriate testing methods and wide variations in epidemiological 
estimates. Therefore, we propose the following definitions and ideas in an effort to improve 
this evidence base, and in so doing improve patient care. At the same time, we are aware that 
this cannot be a complete approach unifying all people working in this field of research, but 
rather a starting point for future development.    
 
 
 
 
 
 
 
 
 
 
Definitions 
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Olfactory dysfunction can be classified as either quantitative, involving alteration in the 
strength but not quality of odours, or qualitative, in which the quality of odours is changed. 
Qualitative disorders, such as parosmia, often involve negatively perceived changes in quality 
of smell. Very often, qualitative changes are found in combination with quantitative changes, 
whereas it is much less frequent to find qualitative changes alone. With regards to qualitative 
changes, parosmia and phantosmia often occur together. Definitions of terms used to describe 
olfactory function and dysfunction are listed in Table 1. 
 
[Table 1] 
 
 
*There is some disagreement in the literature regarding terminology. Whilst ‘parosmia’ is 
generally used to indicate a qualitative olfactory distortion in the presence of a stimulus, it has 
on occasion been used to describe more general olfactory dysfunction (including quantitative 
loss) (14). ‘Dysosmia’ has been used by some to describe any distortion in olfaction, which 
would therefore include both quantitative and qualitative changes (14,15). However, others have 
used this term with reference to qualitative dysfunction in the presence of an odourant 
stimulus only, thus making it synonymous with parosmia (16). Whilst the term ‘cacosmia’ is 
generally accepted as a ‘negatively perceived olfactory distortion’, some consider this either a 
form of parosmia (stimulus present) (16), phantosmia (stimulus absent) (14), or both (15). 
Euosmia is used to describe pleasant qualitative olfactory distortion in the presence of a 
stimulus and can therefore be considered a subtype of parosmia (17). Troposmia is generally 
considered to be synonymous with parosmia (14). 
 
Multiple chemical sensitivity (MCS; also known as ‘Idiopathic Environmental Intolerance’) is 
a condition in which patients describe a range of subjective symptoms following low-level 
exposure to various chemicals. Due to the range of organ systems affected, and disparity of 
offending substances, it has been suggested that MCS is not an organic clinical entity, but 
rather a predominantly psychological condition. This view has been supported by studies 
demonstrating no significant difference in patient response to ‘active’ substances versus 
placebo (18,19). For this reason, MCS has not been considered further in this position paper.   
 
Recommendations: 
 We recommend use of the terms highlighted in bold in the above table, with their 
associated definitions. 
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Epidemiology of Olfactory Dysfunction 
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Though olfactory dysfunction is increasingly recognised, the true prevalence and incidence is 
unclear. Estimates vary significantly according to sample demographics, definitions of 
impairment and assessment technique. The latter is particularly important, and the existing 
literature will therefore be classified according to assessment technique in the following 
sections [for a comprehensive review, please see ref  (20)].  
 
 
Subjective reporting 
Using subjective ‘self-reporting’, early household survey-based studies demonstrated 
conservative prevalence estimates. The 1994 Disability Supplement to the National Health 
Interview Survey (NHIS) addressed chemosensory impairment in a randomly selected cohort 
of 42,000 households (and thereby approximately 80,000 adults over 18) in the United States 
(21). Using adjusted national estimates, the authors concluded that 2.7 million persons (1.4% of 
the US adult population) had experienced a problem with their sense of smell that had lasted 
longer than three months. This prevalence increased markedly with age, with approximately 
40% of persons over the age of 65 reporting smell problems (21).  
 
Newer survey-based studies have reported higher, though still fairly conservative estimates. 
In 2013, results were published from the 2009 Korea National Health and Nutrition 
Examination Survey (KNHANES). In this study, olfactory dysfunction was estimated at 
4.5%, with prevalence increasing with age (22). The US based National Health and Nutrition 
Examination Survey (NHANES) also included a chemosensory component. Two studies 
analysing the prevalence of self-reported olfactory impairment have been published from this 
data. The first of these was by Bhattacharyya and Kepnes in 2015 (23). Using results gathered 
from 3,549 adults between 2011 and 2012, they estimated that 10.6% ± 1.0% of the US 
population had experienced a smell disturbance in the last 12 months. Of these, 50.2% ± 1.8% 
reported their problem to be ‘always there’; 45.2% ± 2.2% reported that their problem ‘comes 
and goes’; and 4.5% ± 0.9% reported that their problem was ‘only present with a cold’. 
Again, prevalence increased with age (odds ratio 1.15, 95% confidence interval 1.00–1.31). 
Sex did not affect prevalence. In 2016, Rawal and colleagues also published results from the 
2011-2012 NHANES project, though from a slightly larger cohort of 3,603 adults (24). They 
reported a higher prevalence of subjective olfactory dysfunction at 23%. However in this 
case, impairment was defined ‘since age 25’, rather than in the preceding 12 months, as was 
used by Bhattacharyya and Kepnes. 
 
Within the context of epidemiological research primarily investigating the prevalence of 
chronic rhinosinusitis, work from the Global Allergy and Asthma European Network 
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(GA2LEN) has demonstrated self-reported smell loss in 7.6% of 57,128 respondents from 
across Europe (25). Within the United States, Hirsch and colleagues demonstrated a prevalence 
of 9.4% subjective smell loss in their source population (26). This was based on results from 
their postal survey of 7,847 people (the aim of which was to determine prevalence of patient 
reported chronic rhinosinusitis).   
 
 
Psychophysical testing 
Previous studies have suggested that olfactory self-rating may be unreliable (27). Therefore, in 
order to increase the accuracy of epidemiological estimates, more objective assessment is 
required in the form of psychophysical testing for odour identification, discrimination or 
threshold. Odour identification tests may be culturally specific and should therefore be 
validated for the target population (for more detail, see ‘psychophysical testing’ in ‘olfactory 
assessment’ section). 
 
In Germany, Landis and colleagues assessed olfactory function in 1,240 non-rhinological 
patients (mean age 41.7 years) presenting to an otorhinolaryngology outpatient clinic. Using 
the odour identification component of the “Sniffin’ Sticks” test battery, they demonstrated 
functional anosmia in 4.7% and hyposmia in 15% of those tested (28). Later, in 2008, 
Vennemann and colleagues performed odour identification testing in a random sample of 
1,312 adults (aged 25-75), as part of the Dortmund Health Study. Based on their 12-item 
screening test an estimated prevalence of 21.6% had impaired olfaction (score of <10), with 
3.6% of these being classified as functionally anosmic (score of ≤ 6) (29). This prevalence 
increased with age and cigarette smoking. 
 
The Skövde population-based study used the Scandinavian Odor Identification Test (SOIT) in 
addition to subjective patient reported measures to determine the rate of olfactory dysfunction 
in Sweden. Their original study population was 1,387 participants (aged ≥ 20 years), 
following which additional adolescent participants were added to produce a sample of 1,713. 
In their original study, the prevalence of self-reported ‘worse-than-normal’ olfactory function 
was 15.3% (30). The prevalence of dysfunction based on the SOIT was higher at 19.1%, with 
13.3% qualifying as ‘hyposmic’ (defined as a SOIT score of 10-12) and 5.8% ‘anosmic’ 
(SOIT score of ≤ 9) (31). In their later study, the prevalence of parosmia was found to be 3.9% 
(32). Another Swedish study, based on data from the Betula project, demonstrated a negative 
correlation between age and olfactory function, as determined through testing with a modified 
SOIT in 1,906 subjects (33). 
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In Spain, the OLFACAT (Olfaction in Catalonia) survey assessed detection, recognition and 
identification of 4 self-administered microencapsulated odourants. Responses were obtained 
from 9,348 persons and normal olfactory function was assigned where the respondent was 
able to detect, recognise and correctly identify all four odourants. ‘Hyposmia’ was assigned 
where a person was unable to correctly detect, recognise or identify one or more odour and 
‘anosmia’ where they were unable to correctly detect, recognise or identify any odours. 
According to this classification, the prevalence of smell dysfunction in this cohort was 19.4% 
for detection (0.3% anosmia, 19.1% hyposmia), 43.5% for recognition (0.2% anosmia, 43.3% 
hyposmia) and 48.8% for identification (0.8% anosmia, 48% hyposmia). This study was 
potentially limited by the questionnaire distribution method, which was through a local 
newspaper, and which may therefore have targeted persons mainly of middle/higher socio-
economic and educational status (34). 
 
Several epidemiological studies utilising psychophysical testing methods have been reported 
from the United States of America. In 2002, results were published from the Epidemiology of 
Hearing Loss Study. Olfaction was tested in 2,491 older adults (aged 53-97) living in Beaver 
Dam, Wisconsin, using the San Diego Odor Identification Test (SDOIT) and subjective 
patient reporting. Using the former method, overall mean prevalence of olfactory dysfunction 
(defined as a SDOIT score of <6 out of 8) was 24.5%, rising to 62.5% for subjects over 80 
years. Self-reported olfactory dysfunction was less common, at only 9.5%, with the ability to 
accurately self-assess olfactory function decreasing with age (35).  
 
The National Social Life, Health and Aging Project (NSHAP) assessed olfaction in a 
nationally representative sample of older adults in the United States during two waves. Odour 
identification was tested in wave one, whilst both identification and threshold scores were 
tested in wave two. During the former, severe olfactory dysfunction was demonstrated in 
2.7% of 3,005 adults aged 57 to 85 years (36). During wave two, olfactory function was shown 
to deteriorate significantly with advancing age, in a cohort of 2,212 subjects aged 62 to 90 
years (37). Of note, this is the only epidemiological study where tests were not only performed 
for screening tests based on odour identification, but also for odour thresholds.  
 
Prevalence of olfactory dysfunction has also been reported from the US based Honolulu-Asia 
Aging Study (HAAS) (38) and the Memory and Aging Project (MAP) (39). Using the Cross-
Cultural Smell Identification Test, the HAAS study demonstrated impaired odour 
identification in around three quarters of adult men over 71 years. Using the same 
psychophysical test, the MAP study reported a prevalence of 55.3% in their cohort of mean 
age 80.6 years.  
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Devanand and colleagues reported data from the Washington Heights/Inwood Columbia 
Aging Project cohort, in which odour identification was tested in 1,169 older adults (mean 
age 80 years) (40). Using the University of Pennsylvania Smell Identification Test, the average 
identification score across the entire cohort was 25.18 ± 7.26, therefore falling at the border 
between ‘severe microsmia’ and ‘microsmia’. During their follow up period, this study went 
on to demonstrate a statistically significant, independent association between olfactory 
dysfunction (particularly anosmia) and increased risk of mortality.  
 
Finally, the Blue Mountains Eye Study assessed olfactory function in 1,636 older adults (aged 
60 and over) in Australia. Using the SDOIT, the authors demonstrated olfactory impairment 
in 27% of their cohort. In addition to demonstrating deterioration in olfactory function with 
age, the authors demonstrated a negative correlation with body mass index, clinically 
supporting the concept that olfaction enhances appetite and food enjoyment  (41).  
 
 
Conclusion: 
 ‘Functional anosmia has a prevalence of approximately 5% of the general population. 
Normal aging significantly contributes to this disease burden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anatomy and Physiology of Olfaction 
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Except in rare circumstances, the perception of odour requires a functional peripheral sensory 
organ and central pathways. 
 
Approximately 6-30 million bipolar receptor cells, or olfactory sensory neurons (OSN), can 
be found in the olfactory neuroepithelium of young adult humans, whose axons collectively 
constitute the olfactory nerve (cranial nerve 1) (42). The cell bodies of these bipolar cells are 
found within the nasal olfactory epithelium. Though traditionally thought to be limited to the 
olfactory cleft, there is uncertainty about the extent of the olfactory neuroepithelium within 
the nasal cavity, especially in younger people (43), but mature and functional OSN can be 
found in humans at the insertion of the middle turbinate (44–48). 
 
Olfactory sensory neurons extend multiple dendritic cilia into an overlying olfactory mucus 
layer, so creating a large surface area for odourant binding. Basally, OSN extend axons in 
bundles (olfactory fila) through the foramina of the cribriform plate towards the olfactory 
bulb. The olfactory bulb is the first relay in the olfactory system and is found immediately 
superior (dorsal) to the cribriform plate and inferior (ventral) to the orbitofrontal cortex. 
Within the olfactory bulb, OSN axons form their first synapse with bulbar glomerular cells. It 
is therefore interesting that OSN are first order excitatory sensory neurons, which extend 
directly from the mucosa of the olfactory cleft into the brain. OSN are also interesting in that 
they are capable of regeneration from the basal cells found within the olfactory 
neuroepithelium although the turn-over time in humans is unclear (49).  
 
Olfactory ensheathing cells (OEC) are supporting glial cells, which are present in the 
peripheral and central olfactory systems (neuroepithelium and olfactory bulb respectively). 
OECs play a facilitative role in the regeneration of OSNs and may putatively be used in future 
treatment of nerve lesions (50,51). The superior turbinate has been demonstrated to be a safe 
area to harvest olfactory mucosa for OEC cell culture (52) and interestingly there is limited 
evidence that OEC yield rates are higher in young compared to old patients or in patients with 
less compared to those with more nasal inflammation (53). 
 
The second order output neurons from the olfactory bulb are the mitral and tufted cells. 
Following signal integration, these neurons extend their axons along the lateral olfactory tract 
towards the structures of the primary olfactory cortex. These structures include: the anterior 
olfactory nucleus, the piriform cortex, the periamygdaloid cortex, the anterior cortical nucleus 
of the amygdala and the rostral entorhinal cortex. Odour processing may also involve 
‘secondary’ and ‘tertiary’ brain areas, including structures such as the hippocampus, 
parahippocampal gyrus, insular cortex, and orbitofrontal cortex (54).  
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In order to initiate olfactory processing, odourants must first reach the olfactory 
neuroepithelium. Here, they become dissolved in the mucus layer and bind with olfactory 
receptors (OR), which are found on the dendritic cilia of the OSN. Olfactory receptors are G-
coupled receptors and binding of the odourant ligand leads to downstream signalling cascades 
involving activation of adenylyl cyclase and subsequent opening of cAMP-dependent cation 
channels (55). Resultant action potential generation is then propagated to the structures 
outlined above. Human gene studies have demonstrated up to 400 active OR genes, though 
humans are able to detect thousands of distinct odours ((56,57) but see also: ref 58). This is made 
possible through complex combinatorial encoding, whereby each odourant ligand is 
recognised by varying combinations of OR (59–61). In addition, other types of chemoreceptors 
have been identified which are likely to be involved in human chemoreception  (62–64). 
 
Finally, it is important to remember that the sensation of smell is also influenced by the 
somatosensory and chemesthetic sensations of the nose: for example the cooling sensation of 
menthol or the prickle of carbon dioxide from carbonated drinks. These sensations are 
mediated in the nose by the trigeminal nerve (65), and there is increasing evidence that 
trigeminal and olfactory functions are closely linked and potentially interdependent (66–69). In 
addition, trigeminal activation is crucial to the perception of nasal airflow (70).  
 
Conclusion: 
 OSN are interesting in that they are capable of regeneration from the basal cells found 
within the olfactory neuroepithelium. 
 
 
 
 
 
 
 
 
 
 
Causes and Classification of Olfactory Loss 
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Previous attempts have been made to classify olfactory dysfunction according to the location 
of presumed pathology, in a similar way to classification used in the auditory system. In this 
way, definitions have included those as in Table 2, below: 
 
[Table 2] 
 
However, anatomical classification in this way may be restrictive. The above categories are 
not mutually exclusive and their use as such may lead to incomplete appreciation of the 
underlying pathophysiology. This is particularly evident with regards to several conditions 
known to cause olfactory dysfunction.  
 
Chronic rhinosinusitis (CRS) is a common inflammatory condition affecting the mucosa of 
the nose and one or more of the paranasal sinuses. It has several distinct phenotypic subtypes 
including CRS with or without polyps. It has been suggested that hyposmia and anosmia 
associated with CRS is caused by mechanical obstruction of odourant transmission to the 
olfactory cleft due to mucosal oedema or polyps (71). Accordingly, opacification of the 
olfactory cleft on CT has been correlated with olfactory function (72). Alone, this would make 
CRS a conductive olfactory dysfunction. However, the link between eosinophilia and 
olfactory dysfunction has been well demonstrated (73–76), and increasing evidence from both 
animal models and human research has suggested that inflammation within the 
neuroepithelium can lead to temporary, reversible interference with odourant 
binding/olfactory perception (77,78). Furthermore, long term inflammation is believed to cause 
neuroepithelial remodelling and replacement with respiratory type epithelium (79,80). 
Additionally, olfactory bulb volumes are decreased in patients with CRS (81). Indeed, Gudziol 
and colleagues have shown that olfactory bulb volume can increase significantly after 
treatment in patients with CRS, compared with controls (82). Therefore, it would appear that 
olfactory dysfunction due to CRS is likely a combination of both conductive, sensorineural 
and even central components in established disease. This argues against the anatomical 
classification of olfactory disorders.  
 
Similar anatomical overlap might be described in posttraumatic olfactory loss. The causative 
pathology in these cases has traditionally been described as severing of the olfactory nerve 
filaments as they cross the cribriform plate to reach olfactory bulb (83). However, the temporal 
course in such patients often does not fit with such dramatic and complete damage, but rather 
with delayed central damage, for example through cortical oedema (84). In addition, the degree 
of posttraumatic olfactory loss can be correlated with central lesions, demonstrated with 
magnetic resonance imaging of the brain (84). In this way, the anatomical site of the lesion 
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might either be sensorineural, central or both. One should also bear in mind that facial lesions 
obtained during head injury may cause obstruction of airflow to the olfactory cleft, thereby 
contributing a conductive element to any olfactory dysfunction.      
 
In order to bypass these limitations in classification, chemosensory research has evolved to 
describe olfactory dysfunction according to putative underlying aetiology. Whilst an 
extensive number of underlying aetiological conditions have been linked to olfactory 
dysfunction, the main causes are as follows: 
 
 Olfactory dysfunction secondary to sinonasal disease 
 Post-infectious olfactory dysfunction 
 Posttraumatic olfactory dysfunction 
 Olfactory dysfunction associated with neurological disease 
 Olfactory dysfunction associated with exposure to drugs/toxins 
 Congenital olfactory dysfunction 
 Olfactory dysfunction associated with aging 
 Other possible causes: iatrogenic damage (sinonasal and skull base surgery, 
laryngectomy), tumours, multiple systemic co-morbidities 
 Idiopathic olfactory dysfunction 
 
The following section will briefly describe the current pathophysiological evidence for the 
above classifications. 
 
Olfactory dysfunction secondary to sinonasal disease 
Rhinosinusitis is the main cause of olfactory loss due to sinonasal disease. This may be either 
acute (lasting less than 12 weeks, with complete resolution of symptoms) or chronic 
rhinosinusitis (lasting 12 weeks or longer). A variety of phenotypic subtypes exist, with 
olfaction being most affected by chronic rhinosinusitis with nasal polyposis (CRSwNP), 
followed by chronic rhinosinusitis without polyps (CRSsNP), non-allergic rhinitis, atrophic 
rhinitis and allergic rhinitis (85). According to the European Position Paper on Rhinosinusitis 
and Nasal Polyps, as well as the American Academy of Otolaryngology-Head and Neck 
Surgery Guidelines, quantitative olfactory dysfunction (in the form of hyposmia or anosmia) 
is one of the key diagnostic symptoms (86,87). 
 
As outlined in the above section, olfactory dysfunction due to CRS is likely caused by a 
combination of factors. These include: obstructed transmission of odourants to the olfactory 
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neuroepithelium caused by oedema, discharge ± polyps; short term reversible ligand-OR 
inflammatory-mediated binding dysfunction (77,78); longer term neuroepithelium remodelling 
(80) and finally olfactory bulb remodelling. (81,82)  
 
Olfactory dysfunction associated with sinonasal disease tends to occur gradually, and 
fluctuates over time (88). It infrequently improves without treatment and is not commonly 
associated with parosmias (89–91). 
 
Given the high prevalence of CRS within the general population (10.9% in Europe (25)), it is 
likely that sinonasal diseases constitute the most frequent cause of olfactory dysfunction (92,93). 
However, such patients are often managed by their general practitioner or general ENT 
surgeons, and are therefore less commonly encountered in specialist smell and taste clinics.  
 
Post-infectious olfactory dysfunction 
Upper respiratory tract infections are a frequent cause of olfactory dysfunction. Indeed, post-
infectious loss is one of the most common presentations seen in specialist clinics (94,95). 
Typically, women are affected more frequently than men, and are middle aged or older at 
presentation (80). The latter may be due to the reduced regenerative ability of the olfactory 
system with advancing age and the accumulation of previous insults (96). Onset is usually 
sudden, and though patients may describe an unusually severe infection, some may be 
unaware of the causative episode. Such cases may therefore be incorrectly labelled as 
idiopathic. Often, patients are affected by parosmia and there is little fluctuation in olfactory 
ability over time (89). Whilst post-infectious olfactory impairment can be permanent, this is 
often not the case. Indeed, it has been suggested that post-infectious olfactory loss improves 
more frequently than in other common aetiological subgroups (94). In their 2006 prospective 
cohort study, Reden and colleagues demonstrated an improvement in the psychophysical test 
scores of approximately one third of 262 patients with post-infectious olfactory dysfunction 
over an observation period of 14 months (97). Whilst higher estimates of recovery have been 
quoted elsewhere in the literature (98), care should be taken in interpreting data based on 
patient self-reporting (99), or where patient numbers are limited (100).  
 
A variety of pathogens may cause post-infectious olfactory dysfunction, including viruses, 
bacteria, fungi, or rare organisms such as microfilaria (16). The most common of these are 
viruses, of which a wide variety have been linked with olfactory dysfunction, including those 
causing the common cold, influenza and HIV (101,102). However, the terminology post-
infectious should be used preferentially to post-viral olfactory dysfunction in order to 
acknowledge the various causative pathogens within this group.  
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The pathophysiology of post-infectious olfactory loss remains poorly delineated, but is 
thought to involve either damage to the olfactory neuroepithelium or central olfactory 
processing pathways (mediated via direct transmission of pathogens to the brain through the 
olfactory nerve) (103,104) . With regards to the former, histological analysis in patients with 
post-infectious olfactory loss shows neuroepithelial remodelling and replacement with 
respiratory type epithelium or occasionally metaplastic squamous epithelium (80,105). The 
number of OSN cells is reduced, they are found in patchy distribution and their morphology 
may be altered: for example they may be shrunken in size with dendrites that do not reach the 
mucosal layer. The associated number of receptors is also reduced (80). Furthermore, olfactory 
bulb volumes are reduced in patients with post-infectious loss and correlate with residual 
olfactory function (106,107). This likely reflects bulb plasticity, partly in response to reduced 
afferent input from the OSN of the neuroepithelium.  
 
Posttraumatic olfactory dysfunction 
Olfactory dysfunction secondary to traumatic injury is a major cause of permanent olfactory 
impairment, and can be ascribed to one or more mechanisms. First, injuries affecting the nose 
may result in mechanical obstruction of odourants to the olfactory neuroepithelium, through 
distorting nasal bone or septal fractures, direct neuroepithelial injury, blood clots, oedema or 
alteration in mucous characteristics (108). The second mechanism involves transection, or 
shearing of the olfactory fila as they traverse the cribriform plate (83). Such transection may 
occur with more severe coup/contra-coup type injuries, or with fractures of the 
midface/anterior skull base, with possible subsequent scarring that may limit axonal 
regeneration and targeting (109,110). Finally, contusions, intraparenchymal haemorrhage or 
resultant gliosis may lead to dysfunction of the central structures involved in olfactory 
processing (84,111). For example, localised contusion of the olfactory bulbs following injury has 
been previously documented (112). However, posttraumatic olfactory loss can occur without 
any visible signs of trauma on imaging studies (84). 
 
Patients with posttraumatic olfactory dysfunction may describe sudden onset loss following 
their injury, however, presentation may also be delayed. Such delay may be in line with the 
patient first noticing their impairment when back in their usual environment. Alternatively, 
delayed presentation may reflect an underlying pathology that does not involve olfactory fila 
transection, but possibly central damage exacted through progressive mechanisms (e.g. 
oedema). Following onset, fluctuation in function is infrequent and patients are often affected 
by phantosmia (and to a lesser degree, by parosmia) (89,113,114). Evidence from several studies 
suggests that recovery is less frequent than in post-infectious loss and whilst prognosis is 
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often poor, recovery may occur in approximately 30% of cases over time depending on the 
severity of the insult (94,97,115–118).  
 
Olfactory dysfunction associated with neurological disease 
Over recent years, the link between olfactory dysfunction and neurological disease has been 
increasingly recognised. Whilst such dysfunction has been associated with epilepsy (119,120), 
myasthenia gravis (121) and stroke (122) it is most commonly seen in neurodegenerative 
conditions such as Parkinson’s disease and Alzheimer’s disease (123–125). Indeed, evidence 
suggests that olfactory dysfunction in Parkinson’s disease (PD) is more common than the 
resting tremor and predates motor symptoms by many years (38,126–128).  
 
Functional imaging studies have demonstrated reduced activity of the hippocampus and 
amygdala in response to odourous stimuli in patients with PD compared with healthy controls 
(129). Histological studies have shown deposition of pathological Lewy bodies and neurites 
within the central olfactory system, including the olfactory bulb and tract, as well as 
decreased neuronal populations within the anterior olfactory nucleus (123,130). However, the 
significance of such changes with regards to the wider neuropathology of PD remains to be 
fully elucidated. Whilst it has been suggested that the olfactory neuroepithelium may offer an 
attractive target for diagnostic biopsies, several studies have shown no significant difference 
in immunohistochemical markers (including different synuclein subtypes) of olfactory 
epithelium in PD patients versus controls (131,132). In addition, work by Huisman and 
colleagues indicates that there are an increased number of (inhibitory) dopaminergic neurons 
in the olfactory bulb which may explain, at least to some degree, hyposmia in PD patients (133) 
(but see also (134)).  
 
Patients with olfactory dysfunction secondary to PD commonly describe a gradual onset, and 
may be initially unaware of their deficit. Such patients do not often report parosmia and are 
unlikely to see any improvement over time (89). Olfactory dysfunction is not affected by 
treatment with anti-PD medications (135).  
 
Olfactory dysfunction associated with exposure to toxins or medications 
Chronic exposure to toxins can result in olfactory dysfunction. Pathogenic agents include 
heavy metals such as cadmium and manganese, pesticides, herbicides and solvents. 
Chemotherapeutic agents and other medications should also be considered in this group. The 
pathological correlates of olfactory dysfunction associated with toxin exposure may involve 
either peripheral neuroepithelial or central damage, the latter being facilitated through 
transport of toxins via the olfactory nerve (16).  
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Table 3 shows an abbreviated list of agents and medications that have been reported to affect 
olfaction. Although many medications have been reported to affect olfaction, carefully 
controlled data for the effects of such drugs on olfaction is limited. 
 
[Table 3] 
 
Congenital olfactory dysfunction 
Certain genetic conditions are known to be associated with congenital dysfunction, most 
notably the developmental endocrine disorder Kallmann syndrome (hypogonadotropic 
hypogonadism). Typically, the diagnosis is made at an age between 12 and 16 years. The 
condition is associated with hypoplastic/aplastic olfactory bulbs and olfactory sulci, and OSN 
of varying number and maturity (80,144–146). Such patients usually have functional anosmia, or 
severe hyposmia from birth. Recent work has also demonstrated olfactory, but not gustatory 
dysfunction in Turner’s syndrome (147), and the Bardet Biedl Syndrome (148).  
 
As MRI scanning becomes more common, non-syndromic hypoplasia/aplasia of the olfactory 
bulb is increasingly recognised. As such, the most frequent cause of congenital or 
‘developmental’ anosmia is now thought to be isolated, non-syndromic, idiopathic congenital 
anosmia with no known genetic cause (149). To make this diagnosis, the normal olfactory bulb 
structure should be hypoplastic or absent and the olfactory sulcus should be shortened (the 
sulcus is seen just above the olfactory bulb on coronal scanning) (150) , though there are 
exceptions to that rule (see (151)). Following diagnosis, patients should undergo genetic, 
endocrinological and paediatric (if appropriate) evaluation in order to delineate the complete 
phenotype of the congenital dysfunction. 
 
Olfactory dysfunction associated with normal aging 
As evidenced through epidemiological studies, olfactory function decreases with age. One 
such study demonstrated olfactory impairment in 62.5% of persons over 80 (35). Furthermore, 
logistic regression analysis of data from the NSHAP study (described above) has 
demonstrated that olfactory dysfunction is a predictor of 5-year mortality, after controlling for 
confounding factors (8,9,152). The link between olfactory dysfunction and mortality has also 
been shown in other studies (please see epidemiology section for more details) (40,153). 
 
Previous work has suggested that olfactory loss with age is not homogeneous across smells: 
sensitivity towards unpleasant odours are usually preserved longer than pleasant ones, 
perhaps due to the formers’ role in environmental navigation and defence (154).   
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The potential causes of olfactory impairment with advancing age are multiple and varied. A 
number of generic physiological changes occur within the nose of the aged that may affect 
olfaction, including parasympathetic/sympathetic dysregulation, reduced mucosal blood flow, 
fibrosis of the cribriform foramina and possibly also age-related mucociliary dysfunction. 
Moreover, age related changes in the olfactory neuroepithelium, olfactory bulbs and central 
olfactory system also occur (155). Changes in the neuroepithelium and olfactory bulb may be in 
part due to the reduced regenerative capacity of the OSN (96). In the absence of efficient OSN 
regeneration, damage from previous insults (e.g. upper respiratory tract infections and 
exposure to toxins) may accumulate to form permanent damage. The reduced olfactory bulb 
volumes seen with advancing age may be partially due to reduced afferent input (and 
consequent trophic effects) in line with OSN damage (82,156,157). 
 
Other disorders associated with olfactory dysfunction 
Other disorders associated with olfactory dysfunction may include intranasal or intracranial 
neoplasms, nasal surgery (e.g., septoplasty 158), endocrine disorders (such as Addison’s 
Disease, Turner’s Syndrome or hypothyroidism), metabolic disorders such as diabetes 
mellitus, hypertension, vitamin B12 deficiency, dysfunction as a complication of surgery (for 
example anterior skull base operations) (16,159,160) or surgery resulting in decreased airflow to 
the olfactory cleft (161). Psychiatric conditions (162,163) and migraine (13,164) have also been linked 
to dysfunction as has radiotherapy (165) or alcohol dependence (166–168).  
 
The role of smoking/nicotine in olfactory loss remains controversial. Several previous studies 
have demonstrated a dose-dependent, negative effect of smoking on olfactory function 
(29,169,170). The underlying pathophysiology of this loss has been suggested to involve increased 
apoptosis of OSN (171) and/or replacement of the olfactory neuroepithelium with squamous 
metaplasia (172). However, other work has shown either negligible (173), or indeed protective 
effects (34) of smoking on olfaction. Work in rats has shown increased odour memory 
following treatment with nicotine agonists (174), and it has been postulated that this may 
contribute to the aforementioned protective effects (34).  Smoking also likely causes nasal 
inflammation, providing another mechanism for olfactory dysfunction. Therefore, although it 
seems to be clear that smoking causes olfactory dysfunction in certain cases, at least for some 
aspects more research is needed.   
 
Idiopathic olfactory dysfunction 
Where an exhaustive assessment has revealed no clear underlying aetiology, olfactory 
dysfunction may be classified as idiopathic. Studies suggest that up to 16% of patients 
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screened at smell and taste centres fall into this category (175). However, care should be 
employed when making this diagnosis, as some such cases may be due to asymptomatic 
upper respiratory infections, or in older patients early neurodegeneration. With respect to the 
latter, a multidisciplinary approach should be considered (176). Further studies are needed in 
this area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Assessment  
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The initial clinical assessment of the olfactory patient is of vital importance: from the history 
alone a diagnosis can usually be made. Accurate diagnosis is required not just to guide 
management but also to give prognostic information. This is particularly important in medico-
legal cases.  
 
When assessing patients with chemosensory impairment, one should bear in mind the close 
association of smell and taste (177). Where a patient complains of reduced or dysfunctional 
taste, often they are in fact suffering from olfactory impairment and describing consequent 
impact on flavour perception (95). For example, the patient may be complaining of retronasal 
olfactory dysfunction but unaware that they are also experiencing orthonasal impairment. 
 
History 
Thorough history taking should include: 
 
Specific impairment 
Is the patient describing a problem with their sense of smell, taste with respect to flavour or 
taste with respect to basic gustatory attributes (sweet/salty/bitter/sour/umami)? Is their 
dysfunction quantitative, qualitative or both? If they are experiencing qualitative dysfunction, 
is this parosmia (stimulus present; parosmia absent when nares closed) or phantosmia 
(stimulus absent) or could there in fact be an internal stimulus, e.g., from the sinuses. If they 
are experiencing quantitative dysfunction, is this affecting all odours, or only specific odours, 
and how severe is their dysfunction in terms of frequency (i.e. daily or less) and intensity (i.e. 
functional anosmia or hyposmia)? What treatment have they had for their dysfunction to date, 
and has this been successful?  
 
Onset 
Sudden onset loss is more common in post-infectious or posttraumatic olfactory dysfunction, 
although in posttraumatic olfactory loss often there is a gap of days and weeks between the 
trauma and recognition of the deficit. Gradual onset is more often seen in sinonasal disease, 
neurodegenerative causes and aging. 
 
Duration 
Dysfunction since childhood is likely to indicate congenital anosmia (and pertinent questions 
regarding other syndromic attributes should be considered). Longer duration of dysfunction 
may be a poor prognostic sign, particularly in cases of chronic rhinosinusitis and 
posttraumatic olfactory dysfunction.  
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Fluctuation 
Olfactory function fluctuates most markedly in cases due to inflammatory disease (CRS or 
allergy). 
 
Other nasal symptoms  
Common symptoms of sinonasal disease (e.g. CRS, allergy) should be assessed, including 
nasal obstruction, rhinorrhoea, postnasal drip, facial pain, sneezing and itching.  
 
Specific impairments and quality of life 
Does the patient rely on their sense of smell professionally (e.g. chef, sommelier)? Is their 
dysfunction causing problems with interpersonal communication (particularly of note in 
mothers) or nutrition (including quantified weight change)? Does the patient describe anxiety 
or depression as a result of their dysfunction? If the patient is suffering from significant 
psychological effects, referral for appropriate assessment and management should be 
considered as appropriate. Does the patient live alone? If so, have they experienced any home 
accidents (e.g. fires, gas leaks etc.)? Such patients should be counselled regarding smoke and 
gas alarms and adherence to ‘use-by’ dates on foods.  
 
Past medical history 
Direct questioning should include previous head injuries, upper respiratory tract infections, 
nasal or neurosurgery and any other chronic diseases that might affect olfaction. Specific 
questions regarding symptoms of undiagnosed neurodegenerative disease should be 
considered in older patients where there is clinical suspicion. Such patients should be referred 
to neurological services as appropriate (178). 
 
Medications 
Current and previous medication history (including chemotherapies) should be obtained as 
well as compliance. The latter may be important where medications are required for control 
of chronic conditions (such as L-thyroxine in hypothyroidism). Where a patient has 
previously been treated with corticosteroids with improvement in smell, it is likely that they 
are suffering from sinonasal disease. 
 
 
 
Allergies 
Allergies to medications, seasonal, perennial and occupational environmental allergens 
should be assessed as well as treatment for these.  
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Smoking and alcohol 
Current smoking and drinking may be associated with both reduced olfaction and taste.  
 
Toxins and occupational exposure 
Exposure to toxins known to cause olfactory dysfunction should be assessed. Additionally, 
exposure to substances that increase the risk of malignancy should be considered (e.g. soft 
and hardwood dusts and sinonasal/nasopharyngeal carcinoma).  
 
Family history  
Family history of olfactory dysfunction may aid in a diagnosis of congenital dysfunction. In 
older patients, a family history of neurodegenerative diseases should be assessed (including 
PD and Alzheimer’s disease).  
 
 
Recommendations:  
 Thorough clinical histories should be sought from all patients. 
 
 
Clinical Examination 
 
Examination should include a full ENT examination. In addition to anterior rhinoscopy, nasal 
endoscopy is desirable, ideally with a 0° Hopkin’s rod lens endoscope (4mm diameter or 
smaller) to start. A 30° endoscope may then be used to facilitate visualisation of the olfactory 
cleft, which is found in the superior nasal cavity, and bounded by the superior and middle 
turbinates laterally and superior nasal septum medially (47). Whilst nasal decongestant may be 
used (179), it should be noted that topical anaesthetic may cause temporary olfactory 
dysfunction (180) and should therefore be avoided until after olfactory testing is performed. 
 
Features to note on endoscopy include: 
 General nasal anatomy including inferior, middle and superior meati. 
 Visibility of olfactory cleft, patency and any abnormalities thereof. Discharge, 
polyps, oedema, crusting, and scarring may be documented using the recently 
proposed Olfactory Cleft Endoscopy (OCES) Scale (181). The use of nasal 
decongestants may be helpful. 
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 Signs of acute or chronic rhinosinusitis (including oedema, discharge (mucopurulent 
or serous), nasal polyps, crusting, scarring). Traditional endoscopic staging of the 
paranasal sinuses in CRS can be performed using the Lund-Kennedy scoring system 
(182) (a more recent endoscopic staging system specific to the olfactory cleft in patients 
with CRS has been developed and correlates with olfactory function (183)).  
 Other sinonasal abnormalities such as benign or malignant neoplasms. Where 
malignancy is suspected a full examination of the mucosal surfaces of the head and 
neck should be undertaken, so requiring thorough oral, pharyngeal and laryngeal 
examinations. 
 
Where a neurological aetiology is suspected, a full cranial nerve and peripheral nervous 
system examination should be undertaken. Tests of memory and cognition should be deferred 
to the appropriate neurological specialists (184) , although appropriate screening tests may be 
performed if feasible.  
 
Where an asymptomatic patient requires assessment for medico-legal purposes, for example 
prior to surgery (e.g. anterior skull base (160)), a full examination of the head and neck should 
be undertaken, including nasal endoscopy, though neurological examination can be omitted if 
appropriate.  
 
Recommendations: 
 Patients with suspected olfactory loss should undergo a full examination of the head 
and neck, including rigid nasal endoscopy with small diameter endoscopes.  
 Asymptomatic patients requiring assessment for medico-legal purposes should also 
undergo a full head and neck examination with endoscopy. 
 Basic neurological examination should be undertaken where there is suspicion of an 
underlying neurological aetiology, though formal and detailed neurocognitive testing 
can be deferred to the appropriate specialists.  
 
 
Olfactory Testing 
 
The method used for assessing olfactory function and dysfunction is vitally important with 
respect to accurate diagnosis, outcome reporting and tracking of olfactory changes over time. 
A limitation of the current literature base is the heterogeneity of assessment techniques used, 
with consequent effect on definitions of impairment and improvement. As highlighted in the 
epidemiology section above, this can lead, for example, to large differences in estimated 
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prevalence rates, and impacts significantly on the generalisability of results, especially where 
non-standardised and potentially unreliable tests are used.  
 
In general, three different types of olfactory testing can be undertaken:  
1. Subjective, patient reported olfactory assessment. 
2. Psychophysical olfactory assessment. 
3. Olfactory assessment using electrophysiological studies or magnetic resonance 
imaging. 
 
 
Subjective Assessment 
Subjective testing can be performed using visual analogue scales, Likert questionnaires, or as 
part of other outcome assessments. For example, the commonly used Sino-Nasal Outcome 
Test (SNOT-22) is a validated patient reported outcome measure for CRS, which assesses 
overall disease burden. However, this contains only one question regarding olfactory 
dysfunction (185). Olfactory-specific patient reported outcome measures, such as the 
Questionnaire of Olfactory Disorders (QOD), appear to have a greater ability to differentiate 
between patients with normosmia versus hyposmia than simple Likert questions analyzed 
from sinus specific questionnaires such as the SNOT-22 and Rhinosinusitis Disability Index 
(186). 
 
However, as discussed briefly above, olfactory self-assessment tends to be unreliable and it 
has been shown that people do not perform well when compared with psychophysical testing 
(27,73,187–191). In 2003 a group of healthy individuals were assessed for correlation between 
subjective, self-reported olfactory ability and composite psychophysical olfactory test scores 
(27). This study found that where subjective rating preceded psychophysical testing (using 
“Sniffin’ Sticks”- see below), there was no significant correlation between the two.  
 
Poor self-rating abilities have also been shown in patient populations. An early study by 
Delank and colleagues showed that 30-40% of CRS patients with impaired olfactory function 
rated themselves as unimpaired (188). In a UK based study of 80 patients presenting to a 
rhinology clinic, only 27.5% accurately reported their olfactory ability (187).  
  
Whilst subjective assessment is useful in characterising the clinical effect of interventions, 
including the ‘minimal clinically important change’ (192), given the above issues, these should 
not be performed in isolation. Rather, when diagnosing olfactory impairment, or assessing the 
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effects of treatment, patient reported outcomes should be used in conjunction with more 
objective forms of assessment, as outlined below.   
 
Recommendations: 
 In patients reporting olfactory dysfunction olfactory assessment should be 
undertaken in order to fully determine disease burden and clinical impact of 
interventions. 
 Where possible, validated questionnaires should be used. Where this is not 
possible, a recognized form of assessment, possibly quantitative and/or anchored, 
such as a visual analogue scale, should be used. 
 Subjective olfactory assessment should not be undertaken in isolation, given its 
poor accuracy. 
 
 
 
Psychophysical Testing 
Psychophysical tests provide a more reliable assessment of olfactory function than subjective 
testing. Similar to an audiogram, during such assessment, an olfactory stimulus is provided 
and the outcome of the test is dependent on the patient’s response. Psychophysical testing 
therefore requires a cooperative subject who can understand and follow instructions, as well 
as communicate choices to the clinician/investigator.  
 
 
Orthonasal psychophysical tools 
Through modification of psychophysical test type, different aspects of olfaction can be 
quantitatively assessed. Broadly, these different aspects can be divided into threshold and 
suprathreshold olfactory function.  
 
Odour threshold is the concentration of an odourant where 50% of the stimuli are detected 
and 50% remain undetectable to a subject. Odour threshold in itself does not require specific 
identification of the odourant stimulus, rather a detection of ‘something’, usually in 
comparison to a blank, odourless stimulus. Where comparison is made between odourant and 
blank stimuli, some degree of short-term, working memory is required. However, this test 
does not utilize episodic or semantic memory (193) and therefore has a lower cognitive burden. 
 
Suprathreshold olfactory testing involves presentation of odour stimuli of sufficient 
concentration such that they should be detectable (i.e. above the threshold level) in an 
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unimpaired person. By varying the odour presented, such tools allow for the testing of odour 
discrimination and identification abilities. Odour discrimination describes the non-verbal 
ability to differentiate between different odours. Odour identification involves both 
recognition of a stimulus and communication of its correct identity (i.e., the ability to name an 
odour). Unprompted odour identification is difficult (194), hence most psychophysical tests 
incorporate either visual or written cues (195).  Unlike odour threshold, performance in the 
suprathreshold tasks of discrimination and identification correlate significantly with a 
subject’s executive function and semantic memory (193). Furthermore, tests of odour 
identification require previous exposure to odour stimulus, and may therefore be culturally 
specific (e.g., the well-known smell of wintergreen in the USA which is almost unknown in 
Germany). This also includes the idea that olfactory tests should be adapted to children (see 
below). For this reason, such tests must be validated in a local population and associated 
normative data collected before use.  
 
The hedonic value of an odour as well as its relative intensity can also be considered forms of 
suprathreshold olfactory testing. Hedonic assessment of an odour, or how pleasant or 
unpleasant an odour is, does not require recognition or identification. However, there is a 
greater emotional component to these ratings and as such, episodic memory may be of greater 
importance compared with the other aspects of olfaction described above. Relative intensity 
can be considered a form of threshold testing. Odour detection threshold is not to be confused 
with odour recognition threshold, which is the concentration of an odour required for 
recognition or identification. As this test involves identification of the odourant, it combines 
elements of both suprathreshold and threshold tasks. Hedonic value, intensity ratings and 
odour recognition thresholds are infrequently used during clinical diagnosis or outcomes 
assessment.  
 
In addition, there are tests that rely on changes in breathing behavior in relation to olfactory 
stimulation, e.g., the Sniff Magnitude Test (196) or  the recording of respiratory patterns in 
relation to olfactometric stimulation (197). The Alcohol Sniff Test (198) uses the distance of the 
odor source from the nostrils as a measure of olfactory function. Subjects close their eyes and 
an opened alcohol pad is placed 30 cm below the nose. With each exhalation the odor source 
is moved 1cm closer until the patient reports smelling alcohol.  
 
The utility of testing for multiple psychophysical components of olfaction (e.g. threshold, 
discrimination and identification) when assessing olfactory dysfunction is debated. Previous 
work by Doty has suggested that different psychophysical tests measure a common source of 
variance, meaning that olfactory impairment and improvement may be effectively assessed 
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using, for example odour identification alone (199). However, this theory is contradicted by 
other work. In 1988 Jones-Gotman and Zatorre described impairment of odour identification 
but not thresholds after selective cerebral excision (200). Similarly, odour identification is 
affected by HIV dementia, whereas odour threshold scores are preserved (201). Work by 
Whitcroft and colleagues demonstrated that the pattern of psychophysical test scores obtained 
in 1,226 subjects, with olfactory loss of varying cause, reflected underlying disease aetiology 
(202). In this study, subjects with olfactory loss due to sinonasal disease were particularly 
impaired in their odour threshold scores, whereas patients with Parkinson’s disease were 
preferentially impaired in suprathreshold olfactory tasks (odour discrimination and 
identification). Taken together, these studies suggest that olfactory threshold preferentially 
tests peripheral causes of olfactory loss (for example due to sinonasal disease), whereas the 
suprathreshold tests of discrimination and identification preferentially assess central or 
cognitive causes of olfactory dysfunction. Therefore, assessing both odour threshold and 
suprathreshold tasks adds to the diagnostic value of the psychophysical tool. 
 
Furthermore, the accuracy of psychophysical tools has been shown to increase when 
composite scores are used. In a study of 2,178 participants of mixed olfactory ability, the 
diagnostic sensitivity of the individual tests odour threshold (T), discrimination (D) and 
identification (I) as compared with composite ‘TDI’ scores, were 64%, 56%, and 47% 
respectively (203). These sensitivities increased where paired test scores were used, but did not 
reach the diagnostic sensitivity of the full composite ‘TDI’ score. Using principle component 
analysis, this study further demonstrated that olfactory threshold scores individually 
explained more of the observed variance than odour discrimination or identification. 
However, these tests require additional effort and take some time to be administered, so 
logistical issues may limit their use. 
 
A variety of orthonasal, psychophysical olfactory tests have been developed for clinical and 
research use. Some of these tests assess just one aspect of olfaction, whilst other assess 
multiple components (204,205). For example, the well known ‘University of Pennsylvania Smell 
Identification Test’ (UPSIT) is a reliable, standardized microencapsulated odour identification 
test, which has been adapted and validated for use in a number of different countries, as well 
as in children (206–209). The UPSIT does not require clinician supervision and is therefore very 
convenient. Accordingly, it is frequently used in the clinical setting, as well as in research (210–
212). The “Sniffin’ Sticks” are another popular psychophysical test battery, the classical 
version of which tests odour threshold (T) and discrimination (D) in addition to identification 
(I) (214). This tool utilises reusable odourant ‘pens’ which are presented to the subject by an 
examiner. A three-alternate forced choice paradigm is employed for odour threshold and 
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discrimination, whilst odour identification is tested using four-alternate forced choice 
written/visual cues. Composite ‘TDI’ scores from the individual subtests are used in 
diagnosis, and higher scores indicate better olfactory function. Again, this assessment tool is 
reliable, has been validated in different countries, and normative data are available for 
children (215–218). Accordingly, “Sniffin’ Sticks” are used extensively in research (128,219,220). 
Other olfactory tests allow for the assessment of some, but not all components of olfaction. 
For example, the Connecticut Chemosensory Clinical Research Center Test assesses odour 
threshold and identification (221).  
 
As mentioned previously, odour identification tests are culturally specific. Certain odours 
may not be familiar to those outside the country where the specific test had been developed. 
For this reason, normative data should ideally be collected from local populations (e.g., 213) or 
alternatively local versions developed. (e.g., 206,207). 
 
Table 4 provides a list of psychophysical olfactory tests which have been used in research 
and/or clinical settings. 
 
[Table 4] 
 
Given the diagnostic utility of assessing multiple aspects of olfaction as described above, in 
combination with the apparent individual value of threshold testing, we suggest that 
psychophysical tools used in the comprehensive assessment of olfaction should ideally 
incorporate threshold testing as well as a test of suprathreshold function, for example 
identification.  
 
Recommendations: 
 Psychophysical assessment tools used in clinical and research settings should include 
tests of odour threshold, and/or one of odour identification or discrimination. Ideally, 
however, testing should include two or three of these subcomponents. 
 Psychophysical assessment tools should be reliable and validated for the target 
population. 
 
Olfactory testing in children 
Measuring olfactory ability in children can be challenging since attention span can be limited 
and, for example, pairing of odor names with the smells may be age and location dependent 
(222). However, olfactory tests have been successfully used in children as young as five, with 
successful completion of the test increasing with age. As an alternative, for very young and/or 
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noncompliant children, the ‘Smell Wheel’ has been used successfully in children as young as 
four (223). The smell wheel is an 11-odour game-like test in which odors are identified using 
words and pictures. A pediatric version of “Sniffin’ Sticks” (a 14 odour identification test) is 
also available (224). 
 
Recommendation 
 When testing olfaction in children, the test should fit the motivation of the child and 
be culturally appropriate.  
 
 
Use of psychophysical tools to diagnose olfactory impairment  
When using psychophysical tools to define olfactory impairment and improvement, it is 
important that reference is made to normative data collected for that test. Hyposmia can be 
separated from normosmia using the 10th percentile of normal test scores gathered from a 
population of young, healthy subjects (209,214). Typically, normosmia is related to young 
healthy people. In contrast, functional anosmia is defined on the basis of the empirical 
distribution of scores obtained by anosmic people (215)(225).  
 
In a clinical setting, psychophysical testing is most commonly performed birhinally, where 
results represent the better of the two sides (27,226). However, increasing evidence suggests that 
lateralised olfactory testing may serve both diagnostic and prognostic utility.  
 
In 2007, Gudziol et al. reported results of monorhinal olfactory testing in 479 healthy 
controls, 765 patients with CRS and 53 patients with sinonasal or olfactory bulb neoplasms 
(227). Using a 12-item screening version of the Sniffin’ Sticks odour identification test, they 
found lateralised differences in function of 3 or more points occurred in 15% of controls, 26% 
of patients with CRS and 32% of those with neoplasms. In 2010, Welge-Lussen and 
colleagues performed a similar study in 518 patients with olfactory dysfunction of mixed 
cause (228). Using the full Sniffin’ Stick test battery they demonstrated significant lateralised 
differences of between 12.5 and 57.1%, depending on cause, the largest side differences being 
in patients with neoplasms. This study went on to demonstrate that lateralised differences in 
threshold score correlated significantly with lateralised differences in discrimination, 
identification and composite TDI scores. Work from Huart and colleagues demonstrated 
asymmetrical olfactory function (using the “Sniffin’ Stick” test battery) in patients with mild 
cognitive impairment, which could be used to efficiently differentiate these patients from 
those with post-infectious impairment or age-matched controls (229). Imaging studies have 
additionally shown correlation between monorhinal test scores and ipsilateral olfactory bulb 
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volume (230). With regards to prognosis, follow-up work by Gudziol et al. showed that patients 
with lateralised olfactory differences were more likely to develop bilateral dysfunction than 
those without side differences (231).  
 
Should lateralized olfactory testing be considered, even in a  time-pressured clinical setting, 
psychophysical testing could begin with monorhinal odour threshold testing. Where there is 
no significant difference in threshold score (for Sniffin’ Sticks, <2.5 points) between the right 
and left sides, testing can continue birhinally. However, where a lateralised difference is 
present, full monorhinal testing should be performed. 
 
Recommendations: 
 Definitions of olfactory impairment should only be made with reference to normative 
values for the psychophysical test being used. 
 Psychophysical testing should ideally begin with monorhinal testing, if feasible. 
Where there is no significant difference in lateralised scores, testing may continue 
bihrinally.  
 
Use of psychophysical tools to define clinically relevant change in olfactory function 
The final consideration when using psychophysical tools to characterise olfactory function is 
the minimum test score change required to indicate clinical improvement or deterioration. 
This is particularly important when reporting the results of longitudinal prognostic studies and 
when assessing interventions: whilst there may be a statistically significant improvement in 
olfactory test scores following some form of treatment, this will not necessarily reflect an 
improvement in subjective disease burden, unless the change is of sufficient magnitude to be 
clinically relevant (i.e. has reached the minimal clinically important difference) (232) (117). 
 
Recommendations: 
 When reporting changes in psychophysical test scores, improvement or deterioration 
in olfactory function should be defined according to established clinical correlates for 
that test. 
 
Psychophysical tests used in screening 
In a clinical context, olfactory screening tests are often required for identification of potential 
impairment in asymptomatic subjects (for example during pre-operative assessment for 
medico-legal reasons). Where screening is required, validated tools have been developed 
which allow for rapid differentiation between normosmia and impaired olfactory function. 
Such tests include the 12 item Cross-Cultural Smell Identification Test (233) or the 12-item 
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identification adaptation of the “Sniffin’ Sticks” test (234). Where abnormalities are identified 
through screening, patients should then undergo full olfactory testing. Olfactory screening 
using dedicated psychophysical tools is felt to be preferable to subjective assessment alone, as 
self-reported symptom questionnaires are not as sensitive or specific as screening odour 
identification testing, particularly for mild hyposmia (235). 
 
Recommendations: 
 Screening for abnormal olfactory function in asymptomatic patients should be 
undertaken using validated psychophysical tools.  
 Patients with abnormal screening results should undergo full olfactory testing. 
 
 
Gustatory testing 
Gustatory dysfunction occurs less frequently than olfactory impairment. The ability to 
distinguish subtleties of food flavor relies heavily on retronasal olfaction, including features 
unique to the human oropharynx and inspiratory airflow (236). Accordingly, when patients 
complain of “abnormal taste”, they are usually suffering from retronasal olfactory dysfunction 
(95). Retronasal olfaction can be tested by asking patients to identify flavoured powders. Such 
tests are useful where there is diagnostic uncertainty. For example, it has been demonstrated 
that in cases of sudden onset olfactory dysfunction, such as posttraumatic loss, both 
orthonasal and retronasal functions decline concurrently. However, more progressive 
dysfunction, such as is seen in sinonasal disease, may preferentially affect the orthonasal 
route whilst retronasal olfaction may be preserved (237,238)  
 
As part of a full olfactory assessment, screening of gustatory function should be undertaken. 
This can be achieved using liquids applied to the tongue for sweet, salty, sour or bitter 
(umami is not commonly screened for as it is poorly identified) (239). Where any abnormalities 
are identified, full gustatory testing should be undertaken using validated tests with normative 
data (240–246).  
 
Recommendations: 
 Comprehensive chemosensory assessment should include gustatory screening for 
sweet, salty, sour and bitter tastes. 
 Full gustatory testing should be performed where abnormalities are identified on 
screening. Ideally, this should include discrimination between retronasal olfaction 
(flavours) and gustatory (taste) abnormalities. 
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Electrophysiology and Functional Imaging 
Whilst subjective and psychophysical tools are sufficient for most clinical and research based 
testing, olfaction can also be assessed in a less subjective way using electrophysiological and 
imaging studies.  
 
Electrophysiological studies include electroencephalography (EEG) and electro-olfactography 
(EOG - the recording of generator potential via an electrode in contact with the olfactory 
neuroepithelium) (247–251). As EEG and EOG are both event-related, delivery of a known 
concentration of odorant must be precisely controlled using an olfactometer, which therefore 
limits the use of such testing for clinical purposes (252). Instead, EEG is useful in medico-legal 
assessment as well as in patients who might not be able to comply with psychophysical 
testing. EOG testing is limited to the research setting. 
 
Functional imaging allows for the identification of brain activity in response to odourous 
stimuli, and includes positron emission tomography (PET) and functional magnetic resonance 
imaging (fMRI) (253). Both techniques utilise changes in cerebral blood flow in order to map 
brain activity changes in response to stimuli (254). However, the use of radioactive isotopes for 
PET makes this a less attractive technique, and fMRI has become more common. The use of 
olfactory functional imaging is again typically limited to the research setting.  
 
Recommendations: 
 Whilst electrophysiological and imaging studies are often reserved for research 
purposes, EEG based olfactory testing can be useful for medico-legal purposes.  
 
 
Other Investigations 
Where olfactory dysfunction has been established, but no cause identified, or further 
information is needed, structural MRI scanning may be helpful (although there is an 
unresolved argument, e.g.: (255) and (256)). In doing so, the olfactory apparatus (olfactory 
neuroepithelium, the olfactory bulb and higher pathways) can be assessed, intracranial 
neoplasms (benign or malignant) excluded, undetected neoplasms in the nasal cavity or 
paranasal sinuses and asymptomatic chronic inflammation of the paranasal sinuses excluded, 
and traumatic brain injury characterised. It is of note that in head trauma the degree of 
olfactory loss can be predicted from brain lesion patterns (84).  
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MRI scanning additionally allows for calculation of olfactory bulb volume, as well as 
olfactory sulcus depth. These structures are affected in a number of conditions, namely: post-
infectious olfactory loss, neurodegenerative diseases, exposure to toxins and congenital 
olfactory dysfunction (145,149). 
 
Adjusted for age and gender, the olfactory bulb volume can be considered as normal, 
hypoplastic or aplastic. If the olfactory bulb volume is taken at the 10th percentile of the 
distribution, one can consider that an abnormal OB volume for a man <45 years is less than 
58mm3 and for a man >45 years is less than 46mm3. A large number of studies have 
demonstrated that olfactory bulb volume is correlated to decreased olfactory perception in 
many disparate diseases (for review see: (257) ). 
 
In patients with CRS, traditional CT staging focused upon the paranasal sinuses correlates 
weakly with olfactory function, however, it appears that volumetric techniques to assess 
opacification of the olfactory cleft may provide additional information regarding olfactory 
function in certain subsets of patients (183). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of olfactory dysfunction 
 
Despite considerable efforts within both the clinical and research communities, long-term, 
effective treatments for olfactory dysfunction largely remain elusive. In the following sections 
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we will outline the more common, or more successful interventions currently available and 
their evidence base.  
 
 
Medications  
Currently, medication is the mainstay of treatment in olfactory dysfunction, with 89% of 
clinicians in a previous European survey preferring topical steroids irrespective of aetiology 
(92) (Table 5).   
 
Corticosteroids 
With regards to olfactory loss secondary to chronic rhinosinusitis ± nasal polyposis, evidence 
exists to support use of both topical and systemic steroids (220,258–262). Indeed, extensive 
guidelines exist for the management of CRS, in which initial medical treatment with 
corticosteroids is recommended (86,87,263–269). We would refer you to these guidelines for 
management of such patients. With regards to non-CRS-related causes of olfactory 
dysfunction, the literature base is less robust, and it is difficult to draw firm conclusions 
regarding the utility of steroids in such patients.  
 
In 2012, Schriever et al. published results from a retrospective analysis of psychophysical 
olfactory scores before and after treatment with 14 days of systemic methylprednisolone. 
Patients with olfactory dysfunction of any cause were included, though the majority (52%) 
had olfactory loss secondary to sinonasal disease. Overall, 26.6% of patients improved by 
more than 6 points on TDI testing (the minimal clinically important difference). However, a 
control group was not included in this study and the validity of findings should be confirmed 
using a prospective, controlled study (270).  
 
Jiang et al. assessed threshold scores following administration of high dose systemic 
prednisolone, in patients with posttraumatic olfactory loss (271). Improved olfaction was seen 
in 16.4% of the study population. However, this modest improvement is difficult to interpret 
given that the study did not include a control group. 
 
Systemic steroids have also been combined with other agents, namely Zinc, vitamin B and 
Ginkgo biloba (272–274). These studies suggest a possible additive benefit for the former two, 
though the additional benefit from Ginkgo biloba did not reach statistical significance.   
 
In addition to anti-inflammatory effects, animal studies suggest that corticosteroids may lead 
to the modification of olfactory gene expression (275). 
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When considering use of systemic corticosteroids, the risk of side effects must be taken into 
account (276–278). At present, evidence-based guidelines regarding the acceptable frequency of 
systemic corticosteroid use do not exist. It therefore falls to the individual clinician to 
exercise the appropriate prudence, particularly in cases of non-CRS related olfactory loss, 
where the evidence supporting steroid use is poor.   
 
Recommendations: 
 Systemic and/or topical steroids should be prescribed in patients with olfactory 
dysfunction secondary to CRS and other inflammatory conditions according to 
existing guidelines. 
 There is limited evidence to support use of steroids for other causes of olfactory 
dysfunction. 
 The risk of potential side effects should be taken into account when prescribing 
systemic corticosteroids.  
  
 
Phosphodiesterase inhibitors 
Phosphodiesterase inhibitors are theorised to improve olfactory function through preventing 
degradation of intracellular cAMP (see anatomy and physiology section). Two studies in 
2009 demonstrated improved olfactory function following phosphodiesterase inhibitor 
administration. The first of these was a prospective study which assessed “Sniffin’ Sticks” 
scores before and after administration of pentoxifylline (which was in this case being given 
for otological conditions) (279). The authors demonstrated a significant improvement in odour 
threshold levels, in keeping with a theorised improvement in peripheral olfactory function. 
However, a mixture of normosmic and impaired patients were included in this study and there 
was heterogeneity in the route of pentoxifylline administration.  The second study by Henkin 
and colleagues utilised an unblinded controlled trial design to assess the effect of oral 
theophylline on olfactory function in hyposmic patients with reduced nasal/saliva 
cAMP/cGMP levels (280). Whilst this study also demonstrated improved olfactory function 
with treatment, the patient population (i.e. those with low cAMP/cGMP levels) and study 
design (an increasing dose of theophylline was given where response was deemed suboptimal 
– a design which may have neglected spontaneous recovery) limits the generalisability of the 
results.  
 
Disappointing results have been demonstrated following double-blind administration of 
sildenafil (a cGMP type 5 phosphodiesterase inhibitor) and caffeine (282,283). Finally, 
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application of topical theophylline to supravital mouse olfactory epithelium, did not lead to 
enhancement of associated EOG recordings (284). 
 
Recommendations: 
 Currently there is insufficient evidence to support use of phosphodiesterase inhibitors 
in the treatment of olfactory dysfunction. 
 
 
Intranasal calcium buffers 
Free calcium within the nasal mucus layer plays a role in negative feedback inhibition of the 
intracellular olfactory signalling cascade (285,286). It is therefore theorised that sequestration of 
such free calcium, using buffer solutions such as sodium citrate, may lead to amplification of 
the olfactory signal and consequent improvement in olfactory function.  
 
In 2005 Panagiotopoulos and colleagues reported improved odour identification scores in 
hyposmic patients treated with intranasal sodium citrate (287). Whilst subgroup analysis 
according to aetiology was not undertaken in this study, it is worth noting that the majority of 
these patients had post-infectious hyposmia. Using a single-blind, placebo-controlled study 
design, Whitcroft et al. also demonstrated an improvement in the odour identification scores 
of patients with post-infectious hyposmia, following administration of intranasal sodium 
citrate (288). A further, prospective and internally controlled study in post-infectious patients 
showed significantly improved composite threshold and identification scores after sodium 
citrate treatment (289). Additional basic and clinical research into the utility of intranasal 
calcium sequestration in post-infectious olfactory loss should be undertaken. 
 
[Table 5] 
 
 
Olfactory training 
Olfactory training involves repeated daily exposure of a subject to a range of odourants. In 
2009, Hummel and colleagues prospectively investigated the utility of such training in a 
group of patients with olfactory loss due to post-infectious, posttraumatic or idiopathic 
aetiologies (300). Forty of these patients underwent twice-daily smell training using 4 
odourants: phenylethylalcohol (rose), eucalyptol (eucalyptus), citronellal (lemon), and 
eugenol (cloves). Compared with baseline psychophysical olfactory test scores (using 
“Sniffin’ Sticks”), the training group significantly improved at 12 weeks, whereas the non-
training group did not. This study was replicated by Haehner et al. in 70 patients with 
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Parkinson’s disease (301). Again, psychophysical test scores significantly improved only in the 
training group (n=35).  
 
A more recent study from Geißler et al.(302) demonstrated improved psychophysical test 
scores following prolonged training (32 weeks), however, these results are limited by lack of 
a comparative control group. A randomised, controlled, multicentre study led by Damm et al. 
in 144 patients also recently showed that olfactory training with high odour concentrations 
resulted in greater improvement than very low odour concentrations (303) indicating that 
olfactory training in fact is not related to sniffing but to olfactory stimulation; this study was 
also the first “quasi placebo” controlled study demonstrating the efficacy of olfactory 
training. Altundag and colleagues also showed improved olfactory function following training 
for 9 months (using 4 different odours every 3 months), with greater benefit being seen 
following longer training duration (304). Whilst each of the latter three studies addressed 
patients with post-infectious olfactory loss, Konstantinidis and colleagues have shown good 
results following training in patients with posttraumatic dysfunction (305). Few studies, 
however, have addressed the effect of training in patients with sinonasal disease (306) (for a list 
of studies see Table 6; for a meta-analysis on studies on olfactory training see (281)). 
 
The exact underlying pathophysiological mechanism for improvement following smell 
training is unknown. However, it is postulated to involve increased regenerative capacity of 
olfactory neurons as a result of repeated odourant exposure (307).  
 
[Table 6] 
 
Given the low associated cost and high safety of olfactory training, it is an attractive treatment 
modality, which can be employed with relative impunity.  
 
Recommendations: 
 Smell training can be recommended in patients with olfactory loss of several 
aetiologies (this treatment requires further evaluation in patients with sinonasal 
disease). 
Surgery 
 
Surgical intervention is largely reserved for treatment of patients with CRS ± polyps. Again, 
as for treatment with steroids, extensive guidelines exist for the use of surgery in such 
patients. Furthermore, two recent Cochrane reviews have been published regarding the utility 
of surgery in these patients, though olfaction is not extensively discussed as an outcome 
  
41 
(313,314). A review of 20 studies published since 1991 shows that olfaction generally improves 
following functional endoscopic sinus surgery (73,188,210,219,220,258,260,315–327). A recent study 
examining olfactory outcomes after surgery for CRS utilised the QOD-NS questionnaire and 
40-item SIT, demonstrating the greatest improvement was seen in patients with the most 
preoperative disease on CT scans (186). There is some difficulty, however, in comparing these 
studies, as marked heterogeneity exists in the methodology used. For example, 5 studies 
utilised only subjective measures of olfactory function, 4 utilised only odour identification 
and 7 only odour threshold testing (Table 8).  
 
The utility of surgery in addressing olfactory dysfunction due to causes other than CRS is less 
well established. In a follow up study, Schriever and colleagues demonstrated that nasal 
septoplasty had no beneficial effects on olfaction as measured at one year (326), though other 
studies have demonstrated benefit (187). The effect of septorhinoplasty on olfaction has not yet 
been sufficiently demonstrated, though some reports suggest that it may lead to improved 
function (328,329). In addition, surgery other than nasal surgery, e.g. gastric bypass does not 
seem to improve olfactory function (330), though there is controversy in the literature (331). 
 
As mentioned above, without an obvious odour present, patients with phantosmia report 
experiencing a very unpleasant smell, often described as ‘rotten meat’, ‘chemical’ or ‘burnt’ 
(in some cases preceding a seizure or migraine; in others the smell is present persistently 
throughout the day). For patients with neurological conditions, the condition often dissipates 
with treatment. However for those without an obvious co-existing condition there is no 
universally accepted treatment. Surgical removal of the olfactory epithelium has been tried in 
a few patients (14,332). This procedure has not been validated and is high risk and should 
therefore be attempted only as a very last resort and only at an experienced, major medical 
centre. Topical application of cocaine hydrochloride can offer temporary relief (333). In some 
patients phantosmia will spontaneously decline over time.   
 
[Table 7] 
 
 
Recommendations: 
 Functional endoscopic surgery for olfactory loss caused by the CRS disease spectrum 
should be undertaken in line with existing guidelines (86). 
 There is presently insufficient evidence to support other surgery types for olfactory 
dysfunction, though further characterisation of the effects of functional 
septorhinoplasty is required.  
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Conclusions 
 
In the preceding sections we have provided an overview of current evidence and 
recommendations for the definition, investigation and management of olfactory dysfunction. 
We hope that these guidelines will encourage clinicians and researchers to adopt a common 
  
43 
language, and in so doing, increase the methodological quality, consistency and 
generalisability of work in this field. 
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TABLES: 
 
Table 1: 
Normosmia Normal olfactory function. 
 
Hyposmia 
(or ‘microsmia’) 
 
Quantitatively reduced olfactory function. 
 
Functional Anosmia Quantitatively reduced olfaction to the extent that the subject has no 
function that is useful in daily life. 
 
Anosmia Absence of all olfactory function. 
 
 
Specific Anosmia 
(or ‘partial 
anosmia’) 
Quantitatively reduced ability to smell a specific odour despite 
preserved ability to smell most other odours. Thought to be a normal 
physiological trait with little clinical significance (12). 
 
Hyperosmia 
(or ‘superosmia’) 
Quantitatively increased ability to smell odours to abnormal level. 
This form of olfactory dysfunction is extremely rare, but has been 
described, for example, in association with migraine (13). 
 
Parosmia  
(or ‘dysosmia’, 
‘cacosmia’, 
‘euosmia’ or 
‘troposmia’)* 
Qualitative dysfunction in the presence of an odorant (i.e. distorted 
perception of an odour stimulus). 
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Phantosmia Qualitative dysfunction in the absence of an odourant (i.e. an 
odourant is perceived without concurrent stimulus, an ‘olfactory 
hallucination’). 
 
 
Orthonasal 
olfaction 
The perception of odourants anteriorly due to airflow from the 
nostrils to the olfactory clefts, e.g. during sniffing. 
 
Retronasal olfaction 
 
The perception of odourants located within the oropharynx, caused 
by airflow to the olfactory clefts via the nasopharynx during 
swallowing or nasal exhalation. Retronasal olfaction forms the basis 
of flavour perception. 
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Table 2: 
Conductive dysfunction  Resulting from blockage of odourant transmission to the 
olfactory neuroepithelium. 
 
Sensorineural dysfunction  
 
 
Resulting from damage/loss of the olfactory neuroepithelium or 
nerve. 
Central dysfunction  
 
Resulting from damage/loss of the olfactory processing 
pathways of the central nervous system. 
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Table 3: 
Agents Medications 
 
 
Acids 
Benzene 
Cadmium 
Chlorine 
Ethyl acetate 
Formaldehyde 
Hydrazine 
Hydrogen sulphide 
Lead 
Mercury 
Nitrous gases 
Paint solvents 
Silicon dioxide 
Trichloroethylene 
Zinc gluconate 
 
 
Anaesthetics (local) 
a. cocaine hydrochloride 
b. procaine hydrochloride 
c. tetracaine hydrochloride 
 
Antimicrobials  
a. aminoglycosides 
b. macrolides 
c. penicillins 
d. tetracyclines 
e. terbinafine 
 
Antithyroid medications  
a. propylthiouracil 
b. thiouracil 
 
 
Chemotherapy 
 
Alpha-Receptor Antagonists  
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Table 4: 
Psychophysical test Olfactory components assessed 
“Sniffin’ Sticks” (original version)  Threshold, discrimination, identification 
Connecticut Chemosensory Clinical Research Center Test Threshold, identification 
T & T Olfactometer Threshold, identification 
University of Pennsylvania Smell Identification Test  Identification 
Smell Diskettes Test Identification 
Cross-Cultural Smell Identification Test Identification 
Pocket Smell Test Identification 
San Diego Odor Identification Test Identification 
Scandinavian Odour Identification Test Identification 
Smell Threshold Test Threshold 
Olfactory Perception Threshold Test Threshold 
Barcelona Smell Test (BAST-24) 
Odourized Marker Test  
Snap & Sniff Olfactory Test System 
Open Essence 
 
Odour detection, identification, memory  
Identification 
Threshold 
Identification 
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Table 5: 
 
Author 
 
 
Year 
 
Study Type 
 
Treatment 
Method 
 
 
Study 
Population; N 
 
Results 
 
Medication 
 
Whitcroft et 
al. (289) 
2016 Prospective, 
controlled 
Intranasal 
sodium citrate 
Patients with 
post-infectious 
olfactory loss 
n=49 
Significant improvement 
in composite threshold 
and identification scores 
after treatment compared 
to placebo 
 
Whitcroft et 
al. (288) 
2016 Prospective, 
controlled 
Intranasal 
sodium citrate 
Patients with 
olfactory loss of 
mixed cause 
n=57 
Significantly improved 
identification scores in 
patients with post-
infectious loss compared 
to placebo 
 
Jiang et al. 
(272) 
2015 Prospective, 
controlled 
Zinc and steroid Traumatic 
anosmia 
n=145 
Zinc and steroid 
application showed 
significant improvement 
compared to “no 
treatment”; no difference 
in effectiveness between 
zinc and steroid 
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Tian et al. (275) 2015 Experimental Dexamethasone 
injection 
Laboratory mice Expression of genes in 
olfactory mucosa 
positively affected by 
glucocorticoids 
Haehner et al. 
(291) 
2015 Cross-
sectional, 
controlled 
Rasagiline 
therapy 
Patients with 
Parkinson’s 
disease 
n=224 
Rasagiline treated patients 
presented with 
significantly better odour 
discrimination when 
Parkinson’s disease 
duration was less than 8 
years 
 
Schöpf et al. 
(292) 
2015 Prospective, 
controlled 
Intranasal 
insulin 
Patients with 
post-infectious 
olfactory loss 
n=10 
 
Immediate (short term) 
improvement of olfaction 
in 2 of 10; 
Haehner et al. 
(293) 
2013 Prospective, 
controlled 
Rasagiline 
treatment 
Patients with 
Parkinson’s 
disease 
n=34 
No significant 
improvement; however 
study end point not yet 
reached 
 
Schriever et 
al. (270) 
2012 Retrospective Systemic 
methyl-
prednisolone 
All aetiologies 
of patients with 
smell loss 
n=425 
Best improvement in 
patients with sinonasal 
disease, but also in other 
aetiologies   
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Lyckholm et 
al. (294) 
2012 Prospective, 
controlled 
Oral zinc Chemotherapy-
related smell 
disorders 
n=58 
No improvement in smell 
loss 
      
Reden et al. 
(295) 
2012 Prospective, 
controlled 
Vitamin A 
treatment 
Patients with 
post-infectious 
and 
posttraumatic 
smell loss 
n=52 
 
No significant effect 
Henkin et al. 
(296) 
2012 Prospective Topical and 
systemic 
administration 
of theophylline  
Patients with 
viral illness, 
allergic rhinitis, 
head trauma, 
congenital 
hyposmia, other 
chronic disease 
processes 
n=10 
 
Oral theophylline 
treatment improved taste 
and smell acuity in 6/10 
after 2-12 months. 
Intranasal theophylline 
treatment improved taste 
and smell acuity in 8/10 
after 4 weeks 
 
Reden et al. 
(297) 
2011 Prospective, 
controlled 
Minocycline 
treatment 
Patients with 
post-infectious 
smell loss 
No significant effect 
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n=55 
 
Panagiotopoul
os et al. (287) 
2011 Prospective Sodium citrate 
buffer solution 
to the nasal cleft 
Patients with 
unspecified 
olfactory loss 
(5), head trauma 
(1), nasal 
surgery (7) and 
post-infectious 
(18), n=31  
 
Measured improvement in 
97% of patients with one 
hour; 74% noticed 
improvement 
Jiang et al. 
(271) 
2010 Prospective Oral high-dose 
steroids 
Posttraumatic 
anosmia 
n=116 
Improvement in some 
patients; possibly 
spontaneous recovery 
Henkin et al. 
(280) 
2009 Prospective Systemic 
administration 
of theophylline 
in increasing 
doses over 2-8 
months 
 
Patients with 
smell loss 
n=312 
Subjective smell loss 
improved in 157  
patients (50.3%) 
Gudziol & 
Hummel (279)  
2009 Prospective Pentoxifylline, 
either i.v. or 
orally 
Patients being 
treated for 
otological 
conditions  
n=19  
Improvement in odour 
thresholds 
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Seo et al. (273) 2009 Prospective, 
controlled 
Corticosteroids 
combined with 
Ginkgo biloba 
Patients with 
post-infectious 
smell loss 
n=71 
Similar improvement both 
in treatment with 
corticosteroids combined 
with Ginkgo biloba and in 
treatment only with 
corticosteroids 
 
Heilmann et 
al. (274) 
2004 Prospective Oral 
prednisolone; 
local 
corticosteroids; 
systemic 
Vitamin B 
Patients with 
olfactory 
dysfunction 
(differing 
aetiologies) 
n=192 
 
Improvement following 
systemic and local 
corticosteroids; also 
improvement with 
systemic Vitamin B after 
6 months 
 
Quint et al. 
(298) 
2002 Prospective, 
controlled 
Caroverine 
application 
Non-conductive 
olfactory 
disorders 
n=77 
 
Significant improvement 
of odour identification 
Hummel et al. 
(299) 
2002 Prospective Oral application 
of alpha-lipoic 
acid 
Olfactory loss 
following 
respiratory 
infections 
n=23 
Significant improvement 
of olfaction; more 
pronounced in patients  
<60 years of age 
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Table 6: 
 
Author 
 
 
Year 
 
Study Type 
 
Study Population; 
N 
 
Results 
 
Olfactory training 
 
Konstantinidis et 
al. (308) 
 
2016 Prospective, 
controlled 
Post-infectious 
olfactory loss 
n=111 
 
Both short (16 weeks) and 
long term (56 weeks) 
training produced 
significantly improved 
olfactory function 
compared with control - 
with long term 
significantly better than 
short 
 
Negoias et al. (309) 2016 Prospective, 
controlled 
Healthy participants Unilateral olfactory 
training produced 
significant increase in 
bilateral OB volume 
Poletti et al. (310) 2016 Prospective Post-infectious and 
posttraumatic 
olfactory loss 
n=96 
Training with light 
molecular weight 
molecules produced 
significantly improved 
PEA threshold compared 
to heavy weight 
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molecules 
Kollndorfer et al. 
(311) 
 
2014 Prospective, 
controlled 
Post-infectious 
anosmia 
n=7 
Olfactory training induced 
changes in functional 
connectivity evidenced 
with fMRI  
Altundag et al. (304) 2015 Prospective, 
controlled 
Post-infectious 
olfactory loss 
n=85 
Longer olfactory training 
with change of odour was 
effective for odour 
discrimination and 
identification 
 
Mori et al. (312) 2015 Prospective, 
controlled 
Healthy children (age 
9-15) 
n=72 
Improved threshold and 
identification in training 
group compared with 
non-training 
Damm et al. (303) 2014 Prospective, 
controlled 
Post-infectious 
olfactory loss 
n=144 
Olfactory training was 
significantly more 
effective with high 
concentration of odours 
and dysfunction <12 
months 
 
Geißler  et al. (302) 2014 Prospective Post-infectious 
olfactory loss 
n=39 
Longer duration of (≥32 
weeks) increased 
effectiveness of training 
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Konstantinidis et 
al. (305) 
2013 Prospective, 
controlled   
Post-traumatic and 
post-infectious 
olfactory loss 
n=119 
 
Significant improvement 
in both groups 
Haehner et al. (301) 2013 Prospective, 
controlled   
Patients with 
Parkinson’s disease 
n=70 
 
Significant increase in 
olfactory function 
Fleiner et al. (306) 2012 Retrospective  Olfactory loss of 
differing aetiologies 
n=46 
 
Improvement of olfaction 
Hummel et al. (300) 2009 Prospective, 
controlled   
Patients with 
olfactory dysfunction 
excluding sinonasal 
disease 
n=56 
 
Improvement of olfactory 
sensitivity 
Wang et al. (307) 2004 Prospective, 
controlled   
Patients anosmic to 
androstenone 
n=33 
Increased sensitivity 
following repeated 
exposure 
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Table 7: 
 
Author 
 
 
Year 
 
Study Type 
 
Treatment 
Method 
 
 
Study Population; 
N 
 
Results 
Surgery 
 
Morrissey et 
al. (334) 
2016 Retrospective Surgical 
resection of 
olfactory 
neuroepithelium 
Patients with 
peripheral 
phantosmia 
n=3 
 
Resolution of 
phantosmia  
Hanci et al. 
(331) 
2016  Prospective Laparoscopic 
Sleeve 
Gastrectomy 
Morbidly obese 
patients with smell 
disorder 
n=54 
 
Improvement of 
olfaction following 
surgery  
 
Randhawa et 
al. (329) 
2016 Prospective Functional 
septorhinoplasty 
All patients listed 
for functional 
septorhinoplasty 
n=43 
Statistically significant 
improvement in 
screening odour 
identification scores, 
but no proven clinical 
benefit 
 
Altun et al. 
(335) 
2015  Prospective Nasal septal 
perforation 
repair 
Patients with septal 
perforation and 
smell disorder 
Improvement in 
olfaction with 
successful closure of 
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n=42 defect; closure success 
in 92.8% 
 
Razmpa et al. 
(212) 
2013 Prospective Aesthetic 
septorhinoplasty 
Patients with 
normal olfaction 
and no nasal 
functional 
abnormalities 
n=102 
 
No significant change 
in odour identification 
scores post-operatively 
Schriever et al. 
(326) 
 
 
 
 
2013 Prospective  Septoplasty ± 
reduction of 
turbinates 
All patients listed 
for nasal 
septal/turbinate 
surgery 
n=44  
 
No significant 
improvement in 
olfactory function at 3.5 
months 
Richardson et 
al. (330) 
 
 
 
 
 
  
2012 Prospective Gastric bypass 
surgery  
Morbidly obese 
patients 
n=55 
Gastric bypass patients 
were more likely to 
have olfactory 
dysfunction pre-
operatively than 
controls, but function 
was not affected by 
surgery 
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Pade et al. (73) 
 
2008 Prospective Septoplasty ± 
reduction of 
turbinates 
 
All patients listed 
for nasal 
septal/turbinate 
surgery 
n=150 
 
At mean 4 months post 
op: 13% improved 
function, 81% stable 
function, 7% 
deterioration in function 
Philpott et al. 
(187) 
2008 Prospective Nasal surgery Patients 
undergoing nasal 
surgery (differing 
aetiologies) 
n=80 
 
Most marked 
improvement in 
septoplasty group 
Leopold (336) 2002 Review article  Intranasal 
removal of 
olfactory 
epithelium 
Patients with 
phantosmia 
n=18 
 
Resolution of 
phantosmia in all but 
one patient 
Leopold et al. 
(332) 
1991 Prospective Intranasal 
removal of 
olfactory 
epithelium 
Patient with 
unilateral 
phantosmia 
n=1 
Resolution of 
phantosmia and return 
of olfactory function 
Stevens et al. 
(337) 
1985 Prospective Nasal surgery Patients 
undergoing nasal 
surgery (differing 
aetiologies) 
n=100 
Similar numbers of 
improved olfaction and 
no change in olfaction 
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LEGENDS FOR TABLES: 
 
Table 1: Definitions of terminology used in olfactory research/practice. 
 
Table 2: Definition of olfactory dysfunction according to anatomical location of lesion. 
 
Table 3: Abbreviated list of agents and medications that affect olfaction (adapted from ref 
(16,136–143)) 
 
Table 4: Different psychophysical tests available. 
 
Table 5: Summary of current clinical and experimental evidence for medication therapy in 
olfactory dysfunction (adapted from ref (290)). 
 
Table 6: Summary of current evidence for olfactory training (adapted from ref (290)). 
 
Table 7: Summary of current evidence regarding the utility of surgery in olfactory 
dysfunction (adapted from ref (290)). Evidence regarding surgery for CRS has not been 
included as this has been extensively described elsewhere (e.g. (86)).   
 
 
 
 
